文献速递眼底病与葡萄膜炎

每月三次阿柏西普注射后按需方案治疗渗出性年龄相关性黄斑变性中超过12个月缓解的发生率与特征:按需方案60个月结果

INCIDENCE AND CHARACTERISTICS OF NEOVASCULAR AGE-RELATED MACULAR WITH OVER A 12-MONTH REMISSION AFTER THREE MONTHLY AFLIBERCEPT ADMINISTRATION: 60 Months Results of a Pro Re Nata Regimen.
PubMed 文献 · Retina · 2024-01-01

研究纳入144只渗出性年龄相关性黄斑变性眼,每月三次玻璃体内注射阿柏西普负荷后按需治疗60个月;82眼(56.9%)至少一次出现≥12个月缓解,累积发生率收敛至60%;缓解组较复发组更年轻且ARMS2风险等位基因频率更低;缓解间隔越长,60个月时视力越好。

要点

  • 144只眼中82眼(56.9%)在60个月内至少一次出现≥12个月缓解。
  • 12个月缓解累积发生率呈平台模式并收敛至60%。
  • 缓解组较复发组更年轻且ARMS2风险等位基因频率更低(均P<0.001)。

核心结论

  • 60个月随访中57%的患者至少一次出现≥12个月缓解,提示无再激活的患者可延长治疗间隔。

研究设计与样本

  • 纳入144只渗出性年龄相关性黄斑变性眼,每月三次玻璃体内阿柏西普注射负荷后按需方案治疗60个月。
  • 根据是否出现12个月缓解分为缓解组和复发组,全部病例进行ARMS2 A69S和CFH I62V基因分型。

主要发现

  • 研究期间82眼(56.9%)至少一次出现≥12个月缓解。
  • 12个月缓解的累积发生率呈平台模式并收敛至60%(y = -166.26x-2.172 + 0.6,R2 = 0.8168)。
  • 缓解组患者较复发组更年轻(P < 0.001)。
  • 缓解组ARMS2基因风险等位基因频率低于复发组(P < 0.001)。
  • 缓解间隔越长,60个月随访时获得的视力越好(P < 0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the characteristics of patients with over a 12-month remission after 3 monthly intravitreal aflibercept injections followed by a pro re nata regimen for exudative age-related macular degeneration (AMD). METHODS: One hundred forty-four eyes with exudative AMD were included. All patients received 3 monthly intravitreal aflibercept injections as a loading dose, followed by an as-needed regimen for 60 months. Patients were classified into the remission and recurrence groups depending on the presence or absence of a 12-month remission. ARMS2 A69S and CFH I62V were genotyped in all cases. RESULTS: During the study, 82 eyes (56.9%) showed 12 months or more remission at least once. The cumulative incidence rate of a 12-month remission showed a plateau pattern and converged to 60% (y = -166.26x-2.172 + 0.6, R2 = 0.8168). Patients in the remission group were younger than those in the recurrence group (P < 0.001) and had less risk allele frequency of the ARMS2 gene than the recurrence group (P < 0.001). The longer the remission interval was prolonged, the better visual acuity was achieved at the 60-month visit (P < 0.001). CONCLUSION: Fifty-seven percent of patients showed a 12-month remission or more at least once during a 60-month follow-up, suggesting that patients with no reactivation can prolong the treatment interval.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Kikushima W, Sakurada Y, Fukuda Y, et al. INCIDENCE AND CHARACTERISTICS OF NEOVASCULAR AGE-RELATED MACULAR WITH OVER A 12-MONTH REMISSION AFTER THREE MONTHLY AFLIBERCEPT ADMINISTRATION: 60 Months Results of a Pro Re Nata Regimen. Retina. 2024. PMID: 38376852. doi:10.1097/IAE.0000000000003994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。